TSLA
Tesla
-- 431.660 RGTI
Rigetti Computing
-- 17.0800 NVDA
NVIDIA
-- 137.010 PLTR
Palantir
-- 79.080 LAES
SEALSQ Corp
-- 9.080 
NEWS
Aileron Therapeutics and Advancium Health Network Announce an Exclusive Option Agreement for the Acquisition of ALRN-6924 for Retinoblastoma
Aileron Therapeutics (NASDAQ: ALRN) and Advancium Health Network have entered into an exclusive option agreement for ALRN-6924, targeting retinoblastoma, a rare pediatric eye cancer. Advancium paid a non-refundable fee for the option to acquire ALRN-6924, with potential additional payments upon exercise. The drug selectively targets MDM2 and MDMX proteins to activate p53-mediated tumor suppression in cancer cells. Retinoblastoma affects approximately 300 cases in the US and 9,000 worldwide annually, primarily in children. ALRN-6924 has shown promising results in preclinical models, demonstrating anti-proliferative activity in RB cell lines and compatibility with intraocular injection.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment